38432-87-0 (11beta-前列腺素 and in f2alpha,9α,11β-Prostaglandin F2)

11beta-前列腺素 and in f2alpha;

Prosta-5,13-dien-1-oicacid, 9,11,15-trihydroxy-, (5Z,9a,11b,13E,15S)-;11β-Prostaglandin F2α;11β-Prostaglandin F2α Lipid Maps MS Standard;CBiol_001989;CTK1C2089;KBio2_000211;KBio2_002779;KBio2_005347;KBio3_000421;KBio3_000422;KBioGR_000211;KBioSS_000211;Prostaglandin F(2a);9alpha,11beta-PGF2;PD020577;C05959;9.ALPHA.,11.BETA.-PGF2;11-Epiprostaglandin F2alpha;11-EPI-PGF2.ALPHA.;9S,11S,15S-trihydroxy-5Z,13E-prostadienoic acid;11-EPIPROSTAGLANDIN F2.ALPHA.;Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11beta,13E,15S)-;CHEBI:27595;(5Z,9alpha,11beta,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid;DTXSID50331533;IDI1_033961;A;SCHEMBL402658;9S,11S,15S-trihydroxy-5Z,13E-prostadienoate;11-epi-PGF2alpha;PXGPLTODNUVGFL-ZWAKLXPCSA-N;11beta-PROSTAGL AND IN F2alpha;LMFA03010036;11-epi-Prostaglandin F2alpha;11-EPI-PROSTAGLANDIN F2.ALPHA.;BML1-G06;DINOPROST TROMETAMOL IMPURITY D [EP IMPURITY];11??-Prostaglandin F2??;SR-01000946487;HMS1791K13;11-epi-Prostaglandin F2a;11beta-Prostaglandin F2;11.beta.-Prostaglandin F2.alpha.;11.BETA.-PGF2.ALPHA.;9alpha,11beta-prostaglandin F2;JG7TH29T3N;PROSTA-5,13-DIEN-1-OIC ACID, 9,11,15-TRIHYDROXY-, (5Z,9.ALPHA.,11.BETA.,13E,15S)-;HMS1989K13;NS00073980;9a,11b PROSTAGLANDIN F2;(Z)-7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate;1ST15215;NCGC00161293-01;Q27103213;HMS3648D12;11beta-PGF2;(5Z,13E,15S)-9alpha,11beta,15-trihydroxyprosta-5,13-dien-1-oic acid;UNII-JG7TH29T3N;CHEMBL1369536;11beta-Prostaglandin F2alpha;11b-PGF2a;HMS3402K13;9.ALPHA.,11.BETA.-PGF2.ALPHA.;9.ALPHA.,11.BETA.-PROSTAGLANDIN F2;(Z)-7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid;SR-01000946487-1;A,11;9;(5Z,9.ALPHA.,11.BETA.,13E,15S)-9,11,15-TRIHYDROXYPROSTA-5,13-DIEN-1-OIC ACID;BSPBio_001491;HMS1361K13;NCGC00161293-03;HY-129953;CS-0108861;AKOS040755271;11beta-PGF2alpha;11-epi-PGF2a;(5Z,13E,15S)-9alpha,11beta,15-trihydroxyprosta-5,13-dien-1-oate;NCGC00161293-04;9alpha,11beta-Pgf2alpha;38432-87-0;NCGC00161293-02;Dinoprost trometamol impurity D [EP];A-Prostaglandin F2;2-azanyl-2-(hydroxymethyl)propane-1,3-diol;7-[3,5-bis(oxidanyl)-2-(3-oxidanyloct-1-enyl)cyclopentyl]hept-5-enoic acid;SMR001821937;cid_44134913;FT-0639301;7-[3,5-Dihydroxy-2-(3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoic acid;FT-0674121;FT-0639300;2-amino-2-methylol-propane-1,3-diol;7-[3,5-dihydroxy-2-(3-hydroxyoct-1-enyl)cyclopentyl]hept-5-enoic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;7-[3,5-dihydroxy-2-(3-hydroxyoct-1-enyl)cyclopentyl]-5-heptenoic acid;FT-0643713;BDBM97180;7-[3,5-dihydroxy-2-(3-hydroxyoct-1-enyl)cyclopentyl]hept-5-enoic acid;146388-90-1;FT-0771357;Prostaglandin F2a;PGF2alpha;CHEMBL2220614;FT-0639170;MLS003107056;NS00096440;2-amino-2-(hydroxymethyl)propane-1,3-diol;7-[3,5-dihydroxy-2-(3-hydroxyoct-1-enyl)cyclopentyl]hept-5-enoic acid;FT-0635335;583E;FT-0639394;11BETA-PROSTAGLANDINF2ALPHA;

MFCD00136056

PXGPLTODNUVGFL-ZWAKLXPCSA-N

1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19-/m0/s1

O[C@H]1C[C@@H]([C@H](/C=C/[C@H](CCCCC)O)[C@H]1C/C=C\CCCC(=O)O)O